福莫斯汀治疗非小细胞肺癌脑转移的临床观察  

The clinical observation of fotemustine in patients of non-small cell lung cancer with brain metastasis

作　　者：贾春祎 张立新[1] 张晓凯[1] 邹勤光[1] 王启文[1] 

机构地区：[1]吉林省肿瘤医院胸外二科,长春130012

出　　处：《癌症进展》2014年第1期89-92,共4页Oncology Progress

摘　　要：目的观察对比福莫司汀及尼莫斯汀治疗非小细胞肺癌脑转移的疗效及不良反应。方法将印例患者随机分人福莫司汀组和尼莫司汀组。福莫司汀组给予福莫司汀100mg／m2，iv，d1、d8、d15，停药4—5周后福莫司汀100mg／m2，iv，d1、d21，休息3周后重复1次；尼莫司汀组给予尼莫司汀2—3mg／kg，iv，d1，停药4～6周后重复给药1次。观察两组的治疗有效率及不良反应情况。结果福莫斯司汀组和尼莫司汀组的有效率分别为83．3％和60．0％，两组间差异有统计学意义（P〈005）。福莫司汀组发生3—4级胃肠道反应的患者占16．7％，略高于尼莫司汀组（10％），但差异无统计学意义。重度骨髓抑制情况福莫司汀组比尼莫司汀组轻。结论福莫司汀治疗晚期非小细胞肺癌脑转移具有临床推广价值。Objective To observe the efficacy and adverse reactions of fotemustine compared with nimustine in non-small cell lung cancer （NSCLC） patients with brain metastasis. Method 60 patients were randomized into fotemustine or nimustine group. Administration method in fotemustine group was 100 mg/m2, iv, dl, d8, d15, then an interruption of 4 -5 weeks, followed by a maintenance period of fotemustine 100mg/m2, iv, dl, d21, which was repeated after three weeks of rest, and evaluation of efficacy and safety was carried out then. Nimustine group accepted nimustine 2-3 mg/kg, iv, dl, then the same regimen resumed after an interruption of 4-6 weeks. Result Response rates （RR） in fotemustine and nimustine group were 83. 3% vs 60. 0%, and there was statistical difference between them （P〈0. 05）. Some 16. 7% patients in foemustine group developed gastrointestinal disorders of grade 3-4, which were slightly higher than that of the nimusitine group （10%）, while the difference was not obvious, and the seriousness of myelosuppression in fotemustine group was comparatively lighter. Conclusion Fotemustine is worth promoting for non-small cell lung cancer with brain metastasis in clinic.

关 键 词：非小细胞肺癌 脑转移 福莫司汀 尼莫司汀 

分 类 号：R734.2[医药卫生—肿瘤]